We are global leader in the laboratory diagnostics market, specializing in the immunodiagnostics and molecular diagnostics segments. For over 50 years our Group has been developing, producing and commercializing diagnostic tests: we support clinical laboratory needs and activities, providing solutions that are reliable, innovative, fully automated and standardized. We continually invest in Research & Development, using our own distinctive expertise in the field to deliver a high level of innovation.
Group Websites
Clinical Areas
We offer the broadest range of specialty tests available in the immunodiagnostics market.
Discover All Areas
Discover Our Menu
LIAISON® XS
All our technology in a new dimension.
LIAISON® XS delivers a high technology solution for immunochemistry tests that allows laboratories to improve efficiency and clinical effectiveness for routine and specialty testing.
Discover All Systems
Worldwide Presence
Our Group consists of 22 branches with offices across 5 continents and manufacturing premises producing its tests in 5 sites around the world.
Where we are
News
14/07/2021
The acquisition of Luminex Corporation represents an important step in the expansion strategy of DiaSorin…
Read the press release
12/07/2021
ECCMID ‘21: Integrated Symposium Diagnosis and immune response of SARS-CoV-2 infection, Flash session TrimericS IgG serology assay in heterologous vaccination.
Register to access
08/02/2021
DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 TrimericS IgG assay, a new quantitative serology test for determination of IgG antibodies against SARS-CoV-2.
Read the press release
26/10/2020
DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 Ag, a new high-throughput antigen test for COVID-19 detection in symptomatic patients.
Read the press release